- Home
- COYA vs ZNTL Comparison
COYA vs ZNTL Comparison
Compare COYA & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- ZNTL
- Stock Information
- Founded
- COYA 2020
- ZNTL 2014
- Country
- COYA United States
- ZNTL United States
- Employees
- COYA N/A
- ZNTL N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- COYA Health Care
- ZNTL Health Care
- Exchange
- COYA Nasdaq
- ZNTL Nasdaq
- Market Cap
- COYA 107.0M
- ZNTL 105.8M
- IPO Year
- COYA 2022
- ZNTL 2020
- Fundamental
- Price
- COYA $5.61
- ZNTL $1.49
- Analyst Decision
- COYA Strong Buy
- ZNTL Buy
- Analyst Count
- COYA 4
- ZNTL 6
- Target Price
- COYA $16.50
- ZNTL $6.53
- AVG Volume (30 Days)
- COYA 116.6K
- ZNTL 729.8K
- Earning Date
- COYA 11-05-2025
- ZNTL 11-11-2025
- Dividend Yield
- COYA N/A
- ZNTL N/A
- EPS Growth
- COYA N/A
- ZNTL N/A
- EPS
- COYA N/A
- ZNTL N/A
- Revenue
- COYA $423,452.00
- ZNTL $26,865,000.00
- Revenue This Year
- COYA $40.80
- ZNTL N/A
- Revenue Next Year
- COYA N/A
- ZNTL N/A
- P/E Ratio
- COYA N/A
- ZNTL N/A
- Revenue Growth
- COYA N/A
- ZNTL N/A
- 52 Week Low
- COYA $4.65
- ZNTL $1.01
- 52 Week High
- COYA $10.24
- ZNTL $4.46
- Technical
- Relative Strength Index (RSI)
- COYA 38.75
- ZNTL 44.94
- Support Level
- COYA $5.37
- ZNTL $1.40
- Resistance Level
- COYA $6.53
- ZNTL $1.50
- Average True Range (ATR)
- COYA 0.43
- ZNTL 0.11
- MACD
- COYA -0.12
- ZNTL -0.04
- Stochastic Oscillator
- COYA 15.89
- ZNTL 21.31
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.